Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 11/20 | 0.42 |
| ▸ | PIM1 | P11309 | 4/20 | 0.39 |
| ▸ | PIM2 | Q9P1W9 | 4/20 | 0.39 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.39 |
| ▸ | PDE5A | O76074 | 1/20 | 0.39 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.37 |
| ▸ | INSR | P06213 | 1/20 | 0.35 |
| ▸ | ITK | Q08881 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6046710 | 0.93 | CHEK1 (0.42) | CHEK1PIM1PIM2PIM3KCNH2 | |
| SCHEMBL6046756 | 0.87 | CHEK1 (0.44) | CHEK1KCNH2 | |
| SCHEMBL6046709 | 0.87 | CHEK1 (0.44) | CHEK1PDE10AKCNH2 | |
| SCHEMBL6046867 | 0.84 | CHEK1 (0.43) | CHEK1KCNH2 | |
| SCHEMBL6046812 | 0.84 | CHEK1 (0.43) | CHEK1KCNH2 | |
| SCHEMBL6046825 | 0.84 | CHEK1 (0.40) | CHEK1PDE10AKCNH2 | |
| SCHEMBL6046693 | 0.83 | CHEK1 (0.42) | CHEK1PDE10AKCNH2 | |
| SCHEMBL6046795 | 0.83 | CHEK1 (0.43) | CHEK1KCNH2 | |
| SCHEMBL6046771 | 0.82 | CHEK1 (0.47) | CHEK1PARP1 | |
| SCHEMBL6046764 | 0.81 | CHEK1 (0.53) | CHEK1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060035920-A1 | Chk-1 inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035920-A1 | Chk-1 inhibitors | CHKA, CHKB, CHEK1 | CHEK1 3/4885PIM1 385/4885PIM2 492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.